文献速递特殊人群用药药物相互作用

羟考酮临床药代动力学与药效学更新

Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone.
PubMed 文献 · Clin Pharmacokinet · 2019-01-01

综述更新羟考酮在新生儿、儿童、孕妇及老年人等特殊人群中的药代动力学数据,并汇总CYP3A诱导剂/抑制剂及CYP2D6抑制剂相关药物相互作用,同时涵盖防滥用制剂及经黏膜、硬膜外等替代给药途径的药代动力学特征。

要点

  • 羟考酮经CYP3A和CYP2D6代谢,合用CYP3A诱导剂/抑制剂或CYP2D6抑制剂需关注相互作用。
  • 特殊人群(新生儿、儿童、孕妇、老年人)药代动力学数据已更新。
  • 防滥用制剂及经黏膜、硬膜外给药途径的药代动力学特征已有报道。

核心结论

  • 羟考酮在特殊人群中的药代动力学数据及药物相互作用信息已有大量更新,临床用药需综合考虑。

研究设计与样本

  • 综述汇总近10年发表的羟考酮药代动力学与药效学数据,包括特殊人群、药物相互作用、防滥用制剂及替代给药途径。

主要发现

  • 羟考酮在新生儿、儿童、孕妇及哺乳期妇女和老年人中的药代动力学数据已有更新。
  • CYP3A诱导剂/抑制剂及CYP2D6抑制剂与羟考酮合用时存在重要药物相互作用。
  • 防滥用羟考酮制剂及经黏膜、硬膜外给药途径的药代动力学特征已有描述。

临床怎么用

  • 临床使用羟考酮时应评估特殊人群药代动力学差异及合并用药的CYP3A/CYP2D6相互作用风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Global oxycodone consumption has increased sharply during the last two decades, and, in 2008, oxycodone consumption surpassed that of morphine. As oxycodone was synthesized in 1916 and taken to clinical use a year later, it has not undergone the same approval process required by today's standards. Most of the basic oxycodone pharmacokinetic (PK) data are from the 1990s and from academic research; however, a lot of additional data have been published over the last 10 years. In this review, we describe the latest oxycodone data on special populations, including neonates, children, pregnant and lactating women, and the elderly. A lot of important drug interaction data have been published that must also be taken into account when oxycodone is used concomitantly with cytochrome P450 (CYP) 3A inducers and inhibitors and/or CYP2D6 inhibitors. In addition, we gathered data on abuse-deterrent oxycodone formulations, and the PK of alternate administration routes, i.e. transmucosal and epidural, are also described.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Kinnunen M, Piirainen P, Kokki H, et al. Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone. Clin Pharmacokinet. 2019. PMID: 30652261. doi:10.1007/s40262-018-00731-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。